<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860548</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT SCSSc-02</org_study_id>
    <secondary_id>SCOT</secondary_id>
    <nct_id>NCT00860548</nct_id>
  </id_info>
  <brief_title>SCOT Scleroderma Treatment Alternative Registry (STAR Registry)</brief_title>
  <official_title>An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Scleroderma Cyclophosphamide Or Transplant (SCOT) Trial is a Phase II/III interventional
      trial comparing two treatments for early, severe scleroderma. These two interventions are
      high dose immunosuppressive therapy followed by autologous stem cell transplantation and
      monthly high dose pulse cyclophosphamide (the later for 12 doses). While standard of care
      might be considered the optimal control arm for a trial such as this one, no such standard of
      care is available for the population of scleroderma patients defined by the eligibility
      criteria for this trial. The rheumatologists on the protocol team believe that the SCOT
      cyclophosphamide regimen represents the best control arm for this study. However, given
      concerns over use of a treatment arm as a control that has not been established as a standard
      of care, this registry was established. The registry will be a prospective, observational
      study of subjects with severe systemic sclerosis (SSc) who are eligible to participate in the
      Scleroderma Cyclophosphamide or Transplantation (SCOT) Study but are denied insurance
      coverage or decline to participate prior to randomization. Subjects will be accrued over the
      same period as the SCOT study. Subjects will follow the course of treatment prescribed by
      their treating physician with no interference from the registry.

      The primary purpose of this study is to document the disease course and outcome in a group of
      participants who are eligible for the SCOT study, but declined to participate, in order to
      determine whether their outcome is better, worse, or no different than those who participate
      in the treatment phase of the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For multiple reasons, the SCOT investigators and the sponsor of the SCOT trial, the Division
      of Allergy, Immunology, and Transplantation (DAIT) of the National Institute of Allergy and
      Infectious Diseases (NIAID), determined that it is important to track the course of a
      'matched' group of patients, who are not exposed to these treatments but receive currently
      available therapy in the community. First, such a group will provide information to determine
      if the SCOT entry criteria do indeed identify these high-risk individuals. More importantly,
      such a group of patients is likely to be treated with a variety of medical regimens,
      including some immunosuppressive therapy with cyclophosphamide or other immunosuppressive
      agents that may modify the natural history of the disease. In evaluating the relative
      efficacy of the two treatment regimens, it will be important to assess whether outcomes in
      the subjects treated under the SCOT protocol have outcome profiles that differ from those
      associated with the matched group of patients treated in the community. One readily available
      group that meets these criteria are those individuals who are otherwise eligible for the SCOT
      trial but fail to be randomized because they either decline to participate or are denied
      insurance coverage to receive the SCOT treatment regimens.

      The duration of this trial is 44 months. Participants will be enrolled over the same period
      as the SCOT trial. Participants will follow the course of treatment prescribed by their
      treating physician with no interference from the registry. All participant contact, including
      obtainment of informed consent and telephone interview regarding outcome measurements will be
      performed by SCOT study personnel at the University of Texas, Houston (one of the SCOT
      transplant centers). Participants will be contacted by phone every 3 months to determine
      vital status, record medical and other therapy, and administer the modified Scleroderma
      Health Assessment Questionnaire (S-HAQ). Medical records will be obtained to verify
      self-reported medical events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>44 months after subject enrollment</time_frame>
    <description>The events will be defined as any one of the following:
Death.
Respiratory failure defined as the need for supplementary oxygen; or
Renal failure, as defined by chronic dialysis &gt; 6 months or renal transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional status as determined by the Modified Scleroderma Health Assessment Questionnaire (m-HAQ/S-HAQ)</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to any cause</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical therapies and procedures (including hospitalizations)</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis and treatment for pulmonary hypertension</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for hyperalimentation</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation whether surgical or auto-amputation</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization or surgery</measure>
    <time_frame>44 months after subject enrollment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <condition>Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>currently available therapy in the community</intervention_name>
    <description>Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with severe systemic sclerosis who are eligible for the SCOT study, but either
        decline to participate or are denied insurance coverage, prior to randomization will be
        invited to participate in this registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No additional inclusion criteria

        Exclusion Criteria:

          -  No additional exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Mayes, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Furst, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter McSweeney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Blood and Marrow Transplant Program, Presbyterian/St. Luke's Medical Center, Rocky Mountain Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie J. Crofford, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Nash, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Sullivan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cellular Therapy, Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas, Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>http://www.sclerodermatrial.org/</url>
    <description>Scleroderma: Cyclophosphamide Or Transplantation (SCOT) Study</description>
  </link>
  <reference>
    <citation>Czirj√°k L, Nagy Z, Szegedi G. Survival analysis of 118 patients with systemic sclerosis. J Intern Med. 1993 Sep;234(3):335-7.</citation>
    <PMID>8354987</PMID>
  </reference>
  <reference>
    <citation>Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski CM, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Reading JC, Williams HJ, Ward JR. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med. 1993 Apr 15;118(8):602-9.</citation>
    <PMID>8452326</PMID>
  </reference>
  <reference>
    <citation>Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993 Jan;125(1):194-203.</citation>
    <PMID>8417518</PMID>
  </reference>
  <reference>
    <citation>Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, et al. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139-48.</citation>
    <PMID>1620814</PMID>
  </reference>
  <reference>
    <citation>Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S29-31. Review.</citation>
    <PMID>12889219</PMID>
  </reference>
  <reference>
    <citation>Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum. 1999 Nov;42(11):2372-80.</citation>
    <PMID>10555033</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

